Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
MeiraGTx Holdings plc (NASDAQ: MGTX) is a vertically integrated, clinical-stage gene therapy company with multiple programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization, gene therapy manufacturing, and a potentially transformative gene regulation technology. The company is focused on developing curative treatments for patients living with serious diseases, initially targeting conditions affecting the eye, central nervous system, and salivary gland, with plans to expand into other areas of unmet medical need.
Serves as the central hub for corporate governance, strategic leadership, global operations management, and investor relations for MeiraGTx.
Strategically situated in a global financial and life sciences hub, providing access to international talent, collaborators, and capital markets.
Characterized by a strong emphasis on scientific innovation, collaboration, and a patient-first approach. The culture fosters cutting-edge research and development in the field of gene therapy.
The London headquarters is key for coordinating MeiraGTx's international research efforts, clinical trial management, and commercialization strategies, benefiting from the UK's robust biotech ecosystem.
MeiraGTx maintains a strategic global presence with its principal executive office in London (UK), significant research and operational facilities in New York (USA), and a specialized gene therapy manufacturing plant in Shannon (Ireland). This international structure enables the company to conduct global clinical trials, foster research partnerships, and prepare for potential commercial activities across North America, Europe, and other key markets.
9 Marylebone Lane
London
England
United Kingdom
Address: 430 East 29th Street, Suite 1140, New York, NY 10016, USA
Facilitates access to U.S. capital markets, leading research institutions, clinical trial sites, and engagement with U.S. regulatory authorities like the FDA.
Address: Western Business Park, Shannon, Co. Clare, Ireland
Leverages Ireland's established biopharmaceutical manufacturing infrastructure, skilled workforce, and supportive regulatory environment. Enables in-house control over a crucial part of the gene therapy supply chain.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, MeiraGTx' leadership includes:
MeiraGTx has been backed by several prominent investors over the years, including:
In the past 12 months (relative to early 2024), MeiraGTx notably strengthened its commercial leadership with the appointment of Stuart M. Arbuckle as Chief Commercial Officer in May 2023. No other significant C-suite departures or appointments have been publicly highlighted, suggesting leadership stability.
Discover the tools MeiraGTx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
MeiraGTx likely follows standard corporate email address patterns. Common formats include using the first initial and last name, or first name separated by a period from the last name, followed by '@meiragtx.com'.
[first_initial][last]@meiragtx.com (e.g., jdoe@meiragtx.com) or [first].[last]@meiragtx.com (e.g., jane.doe@meiragtx.com)
Format
aforbes@meiragtx.com
Example
80%
Success rate
GlobeNewswire • February 29, 2024
MeiraGTx reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on its clinical programs and business operations, including progress in its ophthalmology, salivary gland, and neurodegenerative disease pipelines....more
GlobeNewswire • January 8, 2024
MeiraGTx provided an update on its Phase 2 AQUAx clinical trial evaluating AAV-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia, highlighting ongoing patient enrollment and study progress....more
GlobeNewswire • November 9, 2023
The company announced its financial results for the third quarter of 2023 and provided updates on its various gene therapy programs, including advancements in clinical trials and manufacturing capabilities....more
GlobeNewswire • May 2, 2023
MeiraGTx announced the appointment of Stuart M. Arbuckle as Chief Commercial Officer, tasked with developing and executing the company's global commercial strategy for its gene therapy candidates....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including MeiraGTx, are just a search away.